| Mr Joshua Thomas Bridges, FNP/PMNHNP | |
|
268 Stillwater Ave, Bangor, ME 04401-3945 | |
| (207) 973-9869 | |
| (207) 973-6040 |
| Full Name | Mr Joshua Thomas Bridges |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 268 Stillwater Ave, Bangor, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063897064 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | CNP151073 (Maine) | Secondary |
| 363LP0808X | Nurse Practitioner - Psychiatric/mental Health | CNP151073 (Maine) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| State Of Maine | 7517875131 | 12 |
News Archive
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
Among organ transplant patients, those receiving new lungs face a higher rate of organ failure and death compared with people undergoing heart, kidney and liver transplants. One of the culprits is inflammation that damages the newly transplanted lung.
Columbia Laboratories, Inc. today reported financial results for the three- and six-month periods ended June 30, 2011.
University of Houston researchers are helping the Pentagon build reliable mind-controlled prosthetic devices that military and civilian amputees can use the rest of their lives.
› Verified 3 days ago
| Entity Name | Acadia Hospital Corp. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215940523 PECOS PAC ID: 7719878495 Enrollment ID: O20040323000136 |
News Archive
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
Among organ transplant patients, those receiving new lungs face a higher rate of organ failure and death compared with people undergoing heart, kidney and liver transplants. One of the culprits is inflammation that damages the newly transplanted lung.
Columbia Laboratories, Inc. today reported financial results for the three- and six-month periods ended June 30, 2011.
University of Houston researchers are helping the Pentagon build reliable mind-controlled prosthetic devices that military and civilian amputees can use the rest of their lives.
› Verified 3 days ago
| Entity Name | State Of Maine |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699776146 PECOS PAC ID: 7517875131 Enrollment ID: O20040610001611 |
News Archive
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
Among organ transplant patients, those receiving new lungs face a higher rate of organ failure and death compared with people undergoing heart, kidney and liver transplants. One of the culprits is inflammation that damages the newly transplanted lung.
Columbia Laboratories, Inc. today reported financial results for the three- and six-month periods ended June 30, 2011.
University of Houston researchers are helping the Pentagon build reliable mind-controlled prosthetic devices that military and civilian amputees can use the rest of their lives.
› Verified 3 days ago
| Entity Name | Acadia Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568477297 PECOS PAC ID: 8729019633 Enrollment ID: O20050830000481 |
News Archive
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
Among organ transplant patients, those receiving new lungs face a higher rate of organ failure and death compared with people undergoing heart, kidney and liver transplants. One of the culprits is inflammation that damages the newly transplanted lung.
Columbia Laboratories, Inc. today reported financial results for the three- and six-month periods ended June 30, 2011.
University of Houston researchers are helping the Pentagon build reliable mind-controlled prosthetic devices that military and civilian amputees can use the rest of their lives.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Joshua Thomas Bridges, FNP/PMNHNP 268 Stillwater Ave, Bangor, ME 04401-3945 Ph: (207) 973-9869 | Mr Joshua Thomas Bridges, FNP/PMNHNP 268 Stillwater Ave, Bangor, ME 04401-3945 Ph: (207) 973-9869 |
News Archive
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
Among organ transplant patients, those receiving new lungs face a higher rate of organ failure and death compared with people undergoing heart, kidney and liver transplants. One of the culprits is inflammation that damages the newly transplanted lung.
Columbia Laboratories, Inc. today reported financial results for the three- and six-month periods ended June 30, 2011.
University of Houston researchers are helping the Pentagon build reliable mind-controlled prosthetic devices that military and civilian amputees can use the rest of their lives.
› Verified 3 days ago
Diane M Hill, MSN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1 Northeast Dr, Bangor, ME 04401 Phone: 207-275-3800 Fax: 207-275-3803 | |
Nancy J Fishwick, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 30 Mckinley St, Bangor, ME 04401 Phone: 207-659-3690 | |
Kathrin G Hastey, FNPC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 6 Telcom Dr, Bangor, ME 04401 Phone: 207-947-0147 Fax: 207-990-3365 | |
Judy Splittgerber, PMHNP-BC, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 6 Telcom Dr Fl 2, Bangor, ME 04401 Phone: 207-947-0147 | |
Ms. Constance E Russell, FNPC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 268 Stillwater Avenue, Acadia Hospital Corp, Bangor, ME 04401 Phone: 207-973-6100 Fax: 207-973-6109 | |
Maegan L Woodman, FNPC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 6 Telcom Dr Fl 2, Bangor, ME 04401 Phone: 207-947-0147 Fax: 207-990-3365 | |
Mrs. Alexandria Elizabeth Redmond, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 302 Husson Ave, #2, Bangor, ME 04401 Phone: 207-941-2373 Fax: 207-941-8803 |